Verified peer comparison

PFE vs MRK

Pfizer Inc. compared with Merck & Co., Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

PFE

Pfizer Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

MRK

Merck & Co., Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

PFE: Pharmaceuticals

MRK: Pharmaceuticals

Upside lens

PFE: Commercial growth and pipeline progress from the Seagen portfolio can deepen Pfizer's oncology position and offset maturing products. Successful late-stage readouts, regulatory approvals and launch execution can create new growth sources across oncology, vaccines and specialty care. Manufacturing and operating cost programs can improve productivity and create capacity to fund pipeline investment and debt reduction.

MRK: Continued oncology demand and new indications can sustain growth while Merck expands the franchise beyond its established uses. Increasing contributions from newer medicines across cardiometabolic, respiratory, and HIV markets can diversify growth beyond the largest established products. A robust period of Phase 3 readouts and regulatory milestones could validate Merck's efforts to build a broader set of future growth drivers.

Risk lens

PFE: Loss of exclusivity for major products can cause abrupt revenue erosion if launches and acquired products do not scale quickly enough. Trial failures, safety findings, approval delays or reimbursement restrictions can eliminate expected pipeline value after substantial investment. Realizing returns from acquisitions requires successful integration and commercialization while servicing debt and managing acquired intangible assets.

MRK: Merck remains highly dependent on Keytruda, making future patent expiry, competition, and the pace of portfolio diversification material risks. Declines in vaccines, including demand pressure affecting Gardasil, can offset gains in oncology and newer launches. Large acquisition-related charges and continuing development investment can create earnings volatility before acquired pipeline assets generate returns.